×
About 33,599 results

ALLMedicine™ Hodgkin Lymphoma Center

Research & Reviews  15,531 results

Improved outcomes of high-risk relapsed Hodgkin lymphoma patients after high-dose chemo...
https://doi.org/10.3324/haematol.2021.278311
Haematologica Nieto Y, Gruschkus S et. al.

May 6th, 2021 - High-dose chemotherapy and autologous stem-cell transplant (HDC/ASCT) is standard treatment of chemosensitive relapsed classical Hodgkin lymphoma (cHL), although outcomes of high-risk relapse (HRR) patients remain suboptimal. We retrospectively an...

Conversion to supportive care with biosimilar pegfilgrastim-cbqv enables budget-neutral...
https://doi.org/10.1016/j.leukres.2021.106591
Leukemia Research; McBride A, MacDonald K et. al.

May 6th, 2021 - This pharmacoeconomic simulation (1) assessed the cost-efficiency of converting a panel of 20,000 patients at risk of chemotherapy-induced (febrile) neutropenia (CIN/FN) from reference pegfilgrastim to biosimilar pegfilgrastim-cbqv; (2) estimated ...

Pretreatment whole blood Epstein-Barr virus DNA predicts prognosis in Hodgkin lymphoma.
https://doi.org/10.1016/j.leukres.2021.106607
Leukemia Research; Qin JQ, Yin H et. al.

May 6th, 2021 - The study investigated pretreatment Epstein-Barr virus (EBV) DNA status and its prognostic values in 96 patients newly diagnosed Hodgkin lymphoma (HL). With 13.5 % patients in positive EBV DNA status before therapy, the positive group had inferior...

Successful treatment of EBV-associated Primary CNS Lymphoma due to PTLD, with Ibrutinib...
https://doi.org/10.1111/ajt.16628
American Journal of Transplantation : Official Journal Of... Law SC, Hoang T et. al.

May 4th, 2021 - Primary central nervous system lymphoma (PCNSL) occurring following organ transplantation (post-transplantation lymphoproliferative disorder 'PTLD') is a highly aggressive non-Hodgkin lymphoma. It is typically treated with high-dose methotrexate-b...

see more →

Guidelines  111 results

Adult Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version
https://www.cancer.gov/types/lymphoma/hp/adult-hodgkin-treatment-pdq?cid=eb_govdel
National Cancer Institute

Jan 14th, 2021 - More than 75% of all newly diagnosed patients with adult HL can be cured with combination chemotherapy and/or radiation therapy.[2] Over the last five decades, U.S. national mortality has fallen more rapidly for adult HL than for any other maligna...

Lisocabtagene maraleucel CAR T shows durable response in large B-cell NHL
https://www.healio.com/news/hematology-oncology/20200709/lisocabtagene-maraleucel-car-t-shows-durable-response-in-large-bcell-nhl

Jul 8th, 2020 - In updated results of the pilot study, presented during the ASCO2020 Virtual Scientific Program, researchers showed that lisocabtagene maraleucel induced durable response as a second-line treatment in large B-cell non-Hodgkin lymphoma.

Pembrolizumab prolonged PFS vs. brentuximab vedotin in r/r Hodgkin lymphoma
https://www.mdedge.com/hematology-oncology/article/223065/hodgkin-lymphoma/pembrolizumab-prolonged-pfs-vs-brentuximab

May 31st, 2020 - Pembrolizumab treatment significantly improved progression-free survival versus brentuximab vedotin in a recent randomized, phase 3 trial including patients with relapsed or refractory classical Hodgkin lymphoma, an investigator has reported.

CAR-T continues to show durable responses in indolent non-Hodgkin lymphoma
https://www.healio.com/hematology-oncology/lymphoma/news/online/{b5b2d115-7000-4df9-8743-26711c3bbde1}/car-t-continues-to-show-durable-responses-in-indolent-non-hodgkin-lymphoma

May 30th, 2020 - Axicabtagene ciloleucel induced a 93% response rate among patients with relapsed or refractory indolent non-Hodgkin lymphoma, according to interim results of the phase 2 ZUMA-5 trial presented during the ASCO20 Virtual Scientific Program.

CAR T-Cell Therapy Impresses in Indolent NHL
https://www.medpagetoday.com/meetingcoverage/asco/86783

May 30th, 2020 - Almost 100% of patients with relapsed/refractory indolent non-Hodgkin lymphoma (iNHL) responded to treatment with the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (axi-cel, Yescarta), data from an ongoing study showed.

see more →

Drugs  101 results see all →

Clinicaltrials.gov  16,755 results

Improved outcomes of high-risk relapsed Hodgkin lymphoma patients after high-dose chemo...
https://doi.org/10.3324/haematol.2021.278311
Haematologica Nieto Y, Gruschkus S et. al.

May 6th, 2021 - High-dose chemotherapy and autologous stem-cell transplant (HDC/ASCT) is standard treatment of chemosensitive relapsed classical Hodgkin lymphoma (cHL), although outcomes of high-risk relapse (HRR) patients remain suboptimal. We retrospectively an...

Conversion to supportive care with biosimilar pegfilgrastim-cbqv enables budget-neutral...
https://doi.org/10.1016/j.leukres.2021.106591
Leukemia Research; McBride A, MacDonald K et. al.

May 6th, 2021 - This pharmacoeconomic simulation (1) assessed the cost-efficiency of converting a panel of 20,000 patients at risk of chemotherapy-induced (febrile) neutropenia (CIN/FN) from reference pegfilgrastim to biosimilar pegfilgrastim-cbqv; (2) estimated ...

Pretreatment whole blood Epstein-Barr virus DNA predicts prognosis in Hodgkin lymphoma.
https://doi.org/10.1016/j.leukres.2021.106607
Leukemia Research; Qin JQ, Yin H et. al.

May 6th, 2021 - The study investigated pretreatment Epstein-Barr virus (EBV) DNA status and its prognostic values in 96 patients newly diagnosed Hodgkin lymphoma (HL). With 13.5 % patients in positive EBV DNA status before therapy, the positive group had inferior...

Methotrexate - methotrexate tablet-Accord Healthcare Inc.
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=874c7f43-a3be-4236-89cc-24c44e3c5813

May 5th, 2021 - Methotrexate tablets is a dihydrofolate reductase inhibitor indicated for the: Treatment of adults and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen ( 1.1) Treatment of adults ...

see more →

News  1,097 results

FDA Approves Loncastuximab for Diffuse Large B-Cell Lymphomas
https://www.medscape.com/viewarticle/949934

Apr 25th, 2021 - The US Food and Drug Administration granted an accelerated approval April 24 for a new drug for use in patients with relapsed/refractory diffuse large B-cell lymphomas (DLBCL) who have tried at least two prior systemic therapies. The new product, ...

Combo Provides 'Broad Benefit' Across NHL Subtypes
https://www.medscape.com/viewarticle/949208

Apr 12th, 2021 - The combination of copanlisib plus rituximab led to a 48% reduction in the risk of disease progression or death, when compared with rituximab plus placebo in a phase 3 trial of patients with relapsed, indolent non-Hodgkin lymphoma (NHL). The trial...

Remission of Hodgkin Lymphoma After COVID-19
https://www.medscape.com/viewarticle/945856

Feb 15th, 2021 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. Patients with cancer are considered at risk for COVID-19, but in some cases, could the infection be a good thing? A case report of a patient with ...

Anti-CD20 Therapy for Lymphoma Tied to Worse COVID-19 Outcomes
https://www.medscape.com/viewarticle/945496

Feb 8th, 2021 - NEW YORK (Reuters Health) - Lymphoma patients treated with B-cell-depleting anti-CD20 monoclonal antibodies, such as rituximab or obinutuzumab, may have worse outcomes from COVID-19 infection, according to a study from France. "More than 20 years ...

Fast Five Quiz: Waldenström Macroglobulinemia Workup
https://reference.medscape.com/viewarticle/944100

Jan 31st, 2021 - Waldenström macroglobulinemia (WM) is an indolent subtype of non-Hodgkin lymphoma (NHL) that affects small lymphocytes. WM is rare, accounting for approximately 2% of hematologic malignancies with 1500 cases diagnosed per year in the United States...

see more →

Patient Education  4 results see all →